Search / Trial NCT00000686

A Study of d4T in Patients With AIDS or AIDS-Related Complex Who Cannot Take AZT

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of July 23, 2024

Terminated

Keywords

Drug Evaluation Acquired Immunodeficiency Syndrome Aids Related Complex Antiviral Agents Zidovudine

Description

Of the methods that are being evaluated to treat HIV-infected individuals, AZT has produced the best results to date. Toxic effects in approximately 50 percent of patients receiving AZT may limit its usefulness for prolonged treatment. Long-term treatment may be necessary to prevent progression of early stage HIV infection to AIDS and to prevent secondary transmission. Other drugs that may be equally or more effective than AZT and useful in the long- term treatment of HIV infection must be developed and evaluated. Test-tube and animal studies of d4T show that the drug can inhibit replicatio...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • Diagnosis of AIDS or AIDS related complex (ARC).
  • Previous intolerance to daily doses of up to 1200 mg of zidovudine (AZT) demonstrated by a decrease in hemoglobin levels of 2 - 8.5 g/dl or AZT-related depression of neutrophils of 200 - 750 cells/mm3.
  • Ability to provide informed consent.
  • Prior Medication:
  • Allowed:
  • Zidovudine (AZT).
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following are excluded:
  • AIDS-defining opportunistic infection on enrollment.
  • Intractable diarrhea.
  • History of seizures within past 2 years or currently requiring anticonvulsants for control.
  • Any other clinical conditions or prior therapy which in the opinion of the investigator would make the patient unsuitable for study or unable to comply with the dosing requirements.
  • Concurrent Medication:
  • Excluded:
  • Systemic maintenance or chemoprophylaxis for opportunistic infection (includes dapsone, acyclovir).
  • Systemic therapy with this or any other antiretroviral drug (except zidovudine (AZT)) or investigational drug.
  • Ribavirin.
  • Cytotoxic anticancer therapy.
  • Any agent known as a potent inducer or inhibitor of drug-metabolizing enzymes (includes rifampin and barbiturates).
  • Trimethoprim / sulfamethoxazole (TMP / SMX).
  • Patients with the following are excluded:
  • AIDS-defining opportunistic infection on enrollment.
  • Intractable diarrhea.
  • History of seizures within past 2 years or currently requiring anticonvulsants for control.
  • Any other clinical conditions or prior therapy which in the opinion of the investigator would make the patient unsuitable for study or unable to comply with the dosing requirements.
  • Prior Medication:
  • Excluded within 2 weeks of study entry:
  • Any agent known as a potent inducer or inhibitor of drug-metabolizing enzymes (includes rifampin and barbiturates).
  • Excluded within 1 month of study entry:
  • Systemic therapy with this or any other antiretroviral drug (except zidovudine (AZT)) or investigational drug.
  • Excluded within 3 months of study entry:
  • Ribavirin.
  • Cytotoxic anticancer therapy.
  • Active alcohol or drug abuse sufficient in investigator's opinion to prevent adequate compliance with study therapy.

Attachments

readout_NCT00000686_2024-07-23.pdf

4.5 MB

NCT00000686_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

New York, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0